Cucurbitacin IIa is a triterpenoid isolated exclusively from Hemsleya plants and a non-steroidal anti-inflammatory drug that functions as the main ingredient of prescription Hemslecin capsules and tablets in China.Syn...Cucurbitacin IIa is a triterpenoid isolated exclusively from Hemsleya plants and a non-steroidal anti-inflammatory drug that functions as the main ingredient of prescription Hemslecin capsules and tablets in China.Synthetic biology provides new strategies for production of such valuable cucurbitacins at a large scale;however,the biosynthetic pathway of cucurbitacin IIa has been unknown,and the heterologous production of cucurbitacins in galactose medium has been expensive and low yielding.In this study,we characterized the functions of genes encoding two squalene epoxidases(HcSE1-2),six oxidosqualene cyclases(HcOSC1-6),two CYP450s(HcCYP87D20 and HcCYP81Q59),and an acyltransferase(HcAT1)in cucurbitacin IIa biosynthesis by heterologous expression in Saccharomyces cerevisiae and Nicotiana benthamiana.We achieved high-level production of the key cucurbitacin precursor 11-carbonyl-20b-hydroxy-Cuol from glucose in yeast via modular engineering of the mevalonate pathway and optimization of P450 expression levels.The resulting yields of 46.41 mg/l 11-carbonyl-20b-hydroxy-Cuol and 126.47 mg/l total cucurbitacin triterpenoids in shake flasks are the highest yields yet reported from engineered microbes.Subsequently,production of 11-carbonyl-20b-hydroxy-Cuol by transient gene expression in tobacco resulted in yields of 1.28 mg/g dry weight in leaves.This work reveals the key genes involved in biosynthesis of prescription cucurbitacin IIa and demonstrates that engineered yeast cultivated with glucose can produce high yields of key triterpenoid intermediates.We describe a low-cost and highly efficient platform for rapid screening of candidate genes and high-yield production of pharmacological triterpenoids.展开更多
Dear Editor ,More than 50% of drugs are derived from chemical compounds that have been isolated from various plants (Fabricant and Farnsworth, 2001; Yarnell and Abascal, 2002). With the development of sequencing tec...Dear Editor ,More than 50% of drugs are derived from chemical compounds that have been isolated from various plants (Fabricant and Farnsworth, 2001; Yarnell and Abascal, 2002). With the development of sequencing technology and synthetic biology, we can obtain molecular information from the transcriptomic and genomic data of plants and then utilize bacteria to synthesize desired chemical compounds (Atanasov et al., 2015; Smanski et al., 2016). Increasing numbers of researchers have started to publish omics data generated from herbal plants.展开更多
基金supported by the Major Science and Technology Projects in Yunnan Province(2019ZF011-1)the Fundamental Research Project of Yunnan(202101AS070037)+4 种基金the Science and Technology Innovation team of Yunnan(202105AE160011)the Major Science and Technique Programs in Yunnan Province(202102AE090042)the Yunnan Characteristic Plant Extraction Laboratory(2022YKZY001)the First Projects of Science and Technology Plan in the Biomedical field in 2021(202102AA310048)the National Natural Science Foundation of China(grant nos.81960691 and 82160727).
文摘Cucurbitacin IIa is a triterpenoid isolated exclusively from Hemsleya plants and a non-steroidal anti-inflammatory drug that functions as the main ingredient of prescription Hemslecin capsules and tablets in China.Synthetic biology provides new strategies for production of such valuable cucurbitacins at a large scale;however,the biosynthetic pathway of cucurbitacin IIa has been unknown,and the heterologous production of cucurbitacins in galactose medium has been expensive and low yielding.In this study,we characterized the functions of genes encoding two squalene epoxidases(HcSE1-2),six oxidosqualene cyclases(HcOSC1-6),two CYP450s(HcCYP87D20 and HcCYP81Q59),and an acyltransferase(HcAT1)in cucurbitacin IIa biosynthesis by heterologous expression in Saccharomyces cerevisiae and Nicotiana benthamiana.We achieved high-level production of the key cucurbitacin precursor 11-carbonyl-20b-hydroxy-Cuol from glucose in yeast via modular engineering of the mevalonate pathway and optimization of P450 expression levels.The resulting yields of 46.41 mg/l 11-carbonyl-20b-hydroxy-Cuol and 126.47 mg/l total cucurbitacin triterpenoids in shake flasks are the highest yields yet reported from engineered microbes.Subsequently,production of 11-carbonyl-20b-hydroxy-Cuol by transient gene expression in tobacco resulted in yields of 1.28 mg/g dry weight in leaves.This work reveals the key genes involved in biosynthesis of prescription cucurbitacin IIa and demonstrates that engineered yeast cultivated with glucose can produce high yields of key triterpenoid intermediates.We describe a low-cost and highly efficient platform for rapid screening of candidate genes and high-yield production of pharmacological triterpenoids.
文摘Dear Editor ,More than 50% of drugs are derived from chemical compounds that have been isolated from various plants (Fabricant and Farnsworth, 2001; Yarnell and Abascal, 2002). With the development of sequencing technology and synthetic biology, we can obtain molecular information from the transcriptomic and genomic data of plants and then utilize bacteria to synthesize desired chemical compounds (Atanasov et al., 2015; Smanski et al., 2016). Increasing numbers of researchers have started to publish omics data generated from herbal plants.